NCT05919511 Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
| NCT ID | NCT05919511 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Incyte Corporation |
| Condition | cGVHD |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2023-08-01 |
| Primary Completion | 2027-10-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,500 participants in total. It began in 2023-08-01 with a primary completion date of 2027-10-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years inclusive at the time of signing the ICF * Allogeneic SCT 90 to 180 days prior to enrollment * Able to comprehend and willing to provide informed consent * Willing and able to complete participant-assessment questionnaires either alone or with minimal assistance from a caregiver and/or trained site personnel Exclusion Criteria: * There are no exclusion criteria for this study
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05919511 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying cGVHD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05919511 currently recruiting?
Yes, NCT05919511 is actively recruiting participants. Contact the research team at medinfo@incyte.com for enrollment information.
Where is the NCT05919511 trial being conducted?
This trial is being conducted at Birmingham, United States, Phoenix, United States, Duarte, United States, Los Angeles, United States and 11 additional locations.
Who is sponsoring the NCT05919511 clinical trial?
NCT05919511 is sponsored by Incyte Corporation. The trial plans to enroll 1,500 participants.